Kornø Kristine Tøfting, Aagaard Lise
Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Havemann Law Firm, Frederiksberggade, Copenhagen, Denmark.
J Res Pharm Pract. 2018 Oct-Dec;7(4):205-209. doi: 10.4103/jrpp.JRPP_18_42.
We analyzed prescribing patterns of antipsychotics for children and adolescent affiliated with a Danish Child and Adolescent Mental Health Center) with respect to age, sex, medicine, diagnoses, off-label status, and time.
We included all patients below 19 years of age prescribed antipsychotics during 2007-2008 and as of November 1, 2014. Prescription data included all antipsychotic prescriptions and prescriptions of concomitant psychotropic medications. We defined an antipsychotic user as a patient receiving at least one prescription during the study period, irrespective of any previous history of antipsychotic use. We defined off-label prescribing as prescriptions outside the licensed age group and approved indication.
We analyzed 404 antipsychotic prescriptions that were located for 150 patients. The patients were between 7 and 18 years of age. Two-thirds of the prescriptions were for girls and two-thirds of prescriptions for olanzapine and quetiapine. Totally, 92% of all prescribed antipsychotics were used off-label. For typical antipsychotics, this share was 96% and for atypical antipsychotics 90%. As of November 1, 2014, the total share of off-label antipsychotic prescriptions was 96%, and 63% of these were for medications prescribed outside the approved age group, and 26% for nonlicensed indication(s).
This study demonstrated a high level of off-label prescribing over time with respect to age and indication. The prescribing patterns underpin the need for further economic incentives for pharmaceutical companies to register pediatric indications, particular for off-patent products.
我们分析了丹麦儿童和青少年心理健康中心附属机构中儿童及青少年抗精神病药物的处方模式,涉及年龄、性别、药物、诊断、超说明书用药情况及时间。
我们纳入了2007年至2008年期间以及截至2014年11月1日所有19岁以下开具抗精神病药物处方的患者。处方数据包括所有抗精神病药物处方及同时开具的精神类药物处方。我们将抗精神病药物使用者定义为在研究期间至少接受过一次处方的患者,无论其既往是否有抗精神病药物使用史。我们将超说明书用药定义为超出许可年龄组和批准适应症的处方。
我们分析了为150名患者开具的404份抗精神病药物处方。患者年龄在7至18岁之间。三分之二的处方是给女孩的,三分之二的处方是奥氮平和喹硫平。总体而言,所有开具的抗精神病药物中有92%为超说明书用药。对于典型抗精神病药物,这一比例为96%,非典型抗精神病药物为90%。截至2014年11月1日,超说明书抗精神病药物处方的总比例为96%,其中63%是超出批准年龄组开具的药物,26%是用于未获许可的适应症。
本研究表明,随着时间推移,在年龄和适应症方面超说明书用药的比例较高。这些处方模式表明,需要进一步给予制药公司经济激励,促使其注册儿科适应症,尤其是对于已过专利保护期的产品。